Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Tisagenlecleucel in Primary Central Nervous System Lymphoma
NCT04134117Phase 1Completed
- Start
- Jan 2019
- Primary completion
- Apr 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tisagenlecleucel in primary central nervous system lymphoma (PCNSL). Primary endpoint: Treatment-Related Adverse Events at 12 months. Started Jan 2019; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04134117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134117.